Background. The applicability of clinical trial findings (efficacy) to the routine care setting (effectiveness) may be limited because of study eligibility criteria and volunteer bias. Although well-chronicled in many conditions, the efficacy versus effectiveness of antiretroviral therapy (ART) remains understudied.
Randomized clinical trials (RCTs) are the cornerstone of level I evidence-based medicine treatment recommendations and provide the highest level of evidence [1] . However, some RCT-tested interventions have not performed as well when implemented in routine care settings [2] [3] [4] [5] . Factors such as selection bias introduced by trial eligibility criteria and volunteer bias among participants choosing to participate in research studies have been linked to this discrepancy [2, [4] [5] [6] [7] [8] [9] [10] . Selected patient samples may show improved treatment outcomes in trials (efficacy) when compared with the more heterogeneous population treated through routine care (effectiveness), raising concerns about the applicability of RCT findings to routine care settings.
Efforts to characterize differential efficacy versus effectiveness of treatments have been undertaken in many medical conditions [2, 4-6, 9, 10 ], yet this relationship regarding antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection and AIDS has been notably understudied, particularly in the contemporary ART era [11] . Although numerous studies have separately evaluated either the efficacy or the effectiveness of initial ART regimens when used in RCTs and routine care, respectively, relatively few have studied the comparative effectiveness of treatment modality (RCT vs routine care) on outcomes among patients starting ART in the same clinical setting. Therefore, we conducted a retrospective study to evaluate the impact of receiving initial ART through a clinical trial versus through routine care on short-term viral load and CD4 + cell outcomes among ART-naive individuals initiating therapy. Because treatment-naive ART studies are commonly available, are ingrained in the culture of HIV care at many treatment centers, and provide a means to access medications and laboratories at little to no cost to patients, we hypothesized that volunteer bias would be less apparent in an HIV-infected cohort, relative to cohorts of patients with other diseases. Accordingly, we posited that the sociodemographic composition of those treated through clinical trials would be reflective of the larger clinic population and mirror the characteristics of those patients who received ART through routine care. We further hypothesized that similar virological and CD4 + cell outcomes would be observed between patients treated in clinical trials and those treated through routine care because of the similarities in the patient populations.
METHODS
Sample and procedure. Since 1988, the University of Alabama at Birmingham (UAB) 1917 HIV/AIDS Clinic (1917 Clinic) has provided HIV care for 16000 HIV-infected individuals. The UAB 1917 HIV/AIDS Clinic Cohort Database Project (UAB 1917 Clinic Cohort), which was recently recognized for excellence in information integrity [12] , is a 100% quality controlled, institutional review board-approved prospective clinical cohort study that includes detailed sociodemographic, psychosocial, and clinical information from HIV-infected patients receiving primary HIV and subspecialty care at the clinic [13] . The 1917 Clinic uses a locally programmed electronic medical record (EMR) that imports laboratory values from the central UAB laboratory, requires electronic prescriptions for all medications, and contains detailed encounter notes. Both the UAB 1917 Clinic Cohort and local EMR have been described in detail elsewhere [14] [15] [16] .
A dedicated clinical trials program and staff have been part of the 1917 Clinic since its inception. At our center, RCTs for antiretroviral-naive patients are frequently available and open for enrollment. Prior to study enrollment, providers ascertain patients' willingness to learn more about clinical trial participation and refer interested patients to clinical trial study nurses who screen patients and begin the informed consent process. Once enrolled in a research study, patients receive additional follow-up from study personnel (nurses, mid-level health care providers, and physicians) as determined by specific study protocols, in addition to regular outpatient care at the clinic. Patients who initiate ART through routine care meet with a clinic pharmacist to discuss their regimen. Otherwise, no specific treatment protocol is in place, and all clinic and laboratory follow-up is at the discretion of the primary health care provider (a nurse practitioner or infectious diseases fellow) and attending physician.
Here, we present a retrospective study of the UAB 1917 Clinic Cohort that evaluates antiretroviral-naive patients who initiated ART from 1 January 2000 through 31 December 2006. Patients were categorized into 2 groups: those who initiated ART through a clinical trial, and those who started treatment through routine care. A comparison of viral load and CD4 + cell outcomes between these groups, efficacy in RCTs versus effectiveness in routine care, was the primary focus of this study. Patients whose initial ART regimen lasted longer than 14 days were included.
Independent variables previously reported [17, 18] to impact virological outcomes were chosen a priori and included sociodemographic characteristics (age, sex, race, HIV risk factor, and health insurance status), psychosocial information (history of affective mental disorder, defined as depression, anxiety, or bipolar disease; alcohol abuse; and substance abuse), and baseline laboratory values (CD4 + cell count and plasma HIV load, with viral load expressed in HIV RNA copies/mL). Outcome measures included plasma HIV virological failure (defined as a viral load 150 copies/mL) and change from baseline CD4 + cell count following ART initiation at 6-month and 12-month time points (measure closest to time point in a ‫-09ע‬day window was used).
Statistical analyses. Study variables were evaluated using descriptive statistics to determine the distributions of variables among patients who were treated through routine care versus among those who received ART through a clinical trial. Bivariate analyses were used to identify independent variables associated with clinical trial enrollment. Student's t tests and x 2 tests were applied for continuous and categorical variables, respectively. Univariate and multivariable logistic regression models were fit to determine factors associated with virological failure at 6 and 12 months after ART initiation. Univariate and multivariable linear regression models evaluated factors associated with change from baseline CD4 + cell count value after 6 months and 12 months of therapy. Primary analyses included only patients with available laboratory measures at the 6-month and 12-month time points, and those with missing data were excluded analytically (ie, missing equals missing).
To investigate the potential impact of missing data on study outcomes, sensitivity analyses were conducted for viral load and CD4 + cell count end points at both 6 and 12 months. For those with missing viral load values, single imputation methods were employed to assign outcomes [19] . Missing viral load outcomes were based upon predicted probabilities of virological failure derived from a multivariable model that included patients with available measures. A cut-point for assignment of virological failure was selected erring on the side of misclassification of patients with missing viral load data as having experienced treatment failure (150 copies/mL). For missing 
CD4
+ cell count results, the last value recorded was carried forward for sensitivity analyses. All statistical analyses were performed using SAS, version 9.1.3 (SAS Institute), and statistical significance was defined as . P ! .05 (Table 1) . Overall, most patients were between the ages of 31 and 49 years (66% of patients), male (77%), black (54%), had no health insurance (37%), and were men who have sex with men (MSM; 51%). Baseline CD4 + cell count values were !200 cells/mm 3 in 56% of patients, whereas a baseline viral load !100,000 copies/mL was found in 63% of individuals. Patient histories included diagnoses of affective mental health disorders in 47%, substance abuse in 23%, alcohol abuse in 16%, and opportunistic infections in 31%. The most commonly used third drug was a nonnucleoside reverse-transcriptase inhibitor (NNRTI; 66%) ( Table 2) . In bivariate analysis, clinical trial enrollment was more common among patients with higher baseline CD4 + cell count values (61% of patients in clinical trials vs 40% of patients receiving routine care had CD4 + cell counts 1200 cells/mm 3 ).
RESULTS

Among
Black patients were significantly less likely than others to par- (25) 117 (27) 24 ( (27) 111 (25) 43 (35) 1350 cells/mm 3 93 (17) 63 (14) 30 (25) NOTE. Virological failure was defined as a viral load 150 plasma HIV RNA copies/mL. Univariate and multivariable logistic regression was performed using a "missing equals missing" approach. CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug use; MSM, men who have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor; PIr, ritonavir-boosted protease inhibitor; Unknown/other, currently blinded, raltegravir, or maraviroc.
ticipate in clinical trials (
). HIV risk factor impacted P ! .001 study enrollment, as well; among clinical trial patients, 61% were MSM and 31% were heterosexual, whereas among routine care patients, 49% were MSM and 44% were heterosexual ( ). However, patient age, sex, baseline viral load value, P p .04 insurance status, presence of an affective mental health disorder, substance abuse and alcohol abuse were not associated with clinical trial enrollment ( Table 2) .
Among patients with available viral load measures at 6 months, 66% of those treated through routine care and 71% of those treated through clinical trials achieved virological suppression (viral load !50 copies/mL); at 12 months, 67% and 73% achieved virological suppression, respectively. In primary multivariable analysis (missing equals missing; The increased odds of virological failure associated with black race, as well as with the use of an unboosted protease inhibitor (vs NNRTI ) as a third drug, and the lack of statistically significant associations with age, sex, history of mental health disorder, substance abuse, or alcohol abuse observed in primary analyses were consistent in sensitivity analyses (Table 4) .
Finally, univariate and multivariable linear regression analyses of factors associated with 6-month and 12-month change from baseline CD4 + cell count value were modeled (missing equals missing; Table 5 ). Baseline viral load 1100,000 copies/ mL was associated with a significantly greater increase in CD4 + cell count ( at 6 months; at 12 months). Twelve P ! .001 P p .03 months after initiation of ART, no other factors were associated with a difference in CD4 + cell count response. Notably, similar CD4 + cell count responses were observed in patients treated through a clinical trial and those treated through routine care. Sensitivity analyses (with the last value carried forward; Table  6 ) of CD4 + cell count outcomes yielded findings similar to those of the primary analyses.
DISCUSSION
Among HIV-infected patients who received care at an academic HIV clinic in the Southeastern United States, our primary analysis revealed similar virological suppression (defined as a viral load !50 copies/mL) and CD4 + cell count responses in ARTnaive patients who initiated treatment through a clinical trial and those who initiated treatment through routine care. Though the efficacy versus effectiveness relationship has been examined thoroughly in cardiac care [2, 4, 5] , substance abuse programs [20] , and psychotherapy [9, 10, 21] , it has been notably understudied in HIV/AIDS therapy [11] . A comparison of viral load suppression, CD4 + cell responses, and mortality among patients who received the same protease inhibitor regimens through the Danish Protease Inhibitor Study clinical trial and routine care showed that trial participants had better responses to ART than did patients who received routine care [3] . In contrast, we found that 6-month and 12-month virological failure and CD4 + cell count response were not statistically significantly different between patients who received ART through a clinical trial and those who received treatment through routine care in our study (Tables 3 and 5) .
This study also sought to characterize factors associated with clinical trial enrollment in an HIV-infected cohort. Consistent with prior findings in other specialties [7, 8, 22, 23] and with earlier studies involving HIV infection [24] , we found that black individuals were less likely to participate in clinical trials than were white individuals ( ; Table 2 ). Previously identified P ! .001 factors that may contribute to these findings include mistrust of physicians and researchers [22, [24] [25] [26] [27] [28] [29] , patient fears (eg, being treated as "guinea pigs," being subjected to purposeful infection, or historical precedents such as the Tuskegee syphilis study) [24] [25] [26] [28] [29] [30] [31] , and inequality in requests for research participation among racial/ethnic minorities [23, 26, [31] [32] [33] [34] . In addition to underrepresentation in clinical trial participation, racial disparities in viral load outcomes were also observed. Black race was associated with increased odds of virological failure in our population at both 6 and 12 months in primary and sensitivity analyses (Tables 3 and 4) . Bivariate comparisons of sociodemographic and clinical characteristics among patients with missing versus available viral load and CD4 + cell count values in both the routine care and clinical trial groups showed a statistically significant increase in the frequency of missing data among black patients who received ART through routine care at both 6 and 12 months (data not shown). It has been proposed that limited access to health care and increased frequency of missed clinic appointments may contribute to the poor clinical outcomes observed among black patients with HIV infection [11, 15, 35, 36] ; these factors may also impact the availability of laboratory measures.
We found that individuals with public health insurance were more likely than those with private insurance to experience 6-month virological failure. These findings identify another vulnerable and underserved group at risk for worse health outcomes. Consistent receipt of and adherence to ART among this group with lower socioeconomic status may be complicated by gaps in coverage imposed by public insurance programs [37] and the need to balance the costs of therapy for an initially asymptomatic illness with other economic priorities and competing needs. Health care system reforms that facilitate the acquisition and consistent receipt of therapy in vulnerable populations with limited access to health care are an important prerogative.
Regimen and clinical characteristics associated with virological failure were also identified. Patients with drug regimens that included unboosted protease inhibitors had a higher rate of virological failure, which result is not surprising given the multitude of data that illustrate the poor outcomes associated with use of unboosted protease inhibitors, compared with other ART strategies (Tables 3 and 4 ) [38] [39] [40] . Elevated baseline viral load has also been linked to increased risk of subsequent virological failure [11, 41, 42] , which is a finding echoed by our study. With regards to analyses concerning the change from initial CD4 + cell count value, only baseline viral load 1100,000 copies/mL was associated with a statistically significant CD4 + cell count change at 12 months (Tables 5 and 6 ). In sensitivity analyses of virological outcomes using imputation methods, significant differences in 6-month virological failure were not observed between patients who were treated in clinical trials and those who received routine care, in accordance with primary analyses (Table 4) . However, at 12 months, ART receipt through routine care was associated with a trend toward increased odds of virological failure (OR, 1.77; 95% CI, 0.98-3.23). We suspect that this trend may reflect the greater frequency of missing viral load values among the routine care group (in the routine care group, 126 [28%] of patients had missing values; in the clinical trial group, 13 [11%] of patients had missing values), which may relate to several factors. Volunteer and selection bias for clinical trial participation may result in a sample of patients who are more likely to attend clinic appointments and have laboratory measures obtained than are patients in the routine care population. Study selection criteria are known to contribute to differences in clinical trial enrollment rates among different groups [2, 5, 6, 8, 9, 24] and may have played a role in the current study. Participation in a clinical trial also entails close follow-up with study personnel. Such close monitoring and aggressive rescheduling after missed study visits is beyond the capacity of our clinic for all patients in routine clinical care. In summary, regarding efficacy versus effectiveness in HIV therapy, 6-month virological outcomes were consistent in primary and sensitivity analyses, although a trend toward differences in viral load outcomes appeared at 12 months in sensitivity analyses. By using 2 strategies to evaluate the impact of missing data on virological outcomes, a more complete understanding of the efficacy-effectiveness gap is obtained, which underscores the importance of a comprehensive approach.
Our findings should be interpreted with respect to the limitations of our study. As a retrospective study from a single HIV cohort, our findings may not be generalizable to other national or international settings, although our analysis may provide insights applicable to such settings. As with all observational studies, we were able to identify associations but cannot attribute causality. Although we controlled for measured confounders using multivariable models, there is the potential for unmeasured confounding, which is inherent to observational studies and which may impact outcomes interpretation. Other studies have implicated patient education level in contributing to clinical trial participation [7, 8, 22, 24-28, 30, 31 ], but we were unable to systematically ascertain this variable in our sample. Because of our modest sample size, we were able to assess treatment modality (clinical trial vs routine care) but had insufficient numbers to assess efficacy versus effectiveness at the regimen level. Such analyses are on-going through larger, multisite cohort collaborations.
A notable strength of this study is the use of multiple strategies to analyze the impact of missing data on outcomes, which enabled a more comprehensive understanding of the efficacy versus effectiveness relationship within the constraints of the measurements available. Many prior studies of HIV outcomes have neither explicitly stated the handling of missing data nor evaluated the impact of missing data on outcomes interpretation.
In conclusion, clinical research studies have played a vital role in the improvement of HIV treatment and outcomes. However, it is critical to evaluate both the efficacy and the effectiveness of therapy to ensure that the results obtained from clinical trials are generalizable to other populations treated through routine care. In primary analyses evaluating patients with available measures, we found similar 6-month and 12-month virological failure and CD4 + cell count responses among antiretroviral-naive patients treated through routine care, compared with responses among those patients who participated in clinical trials. These findings provide insight into the efficacyeffectiveness relationship of ART for HIV infection and suggest that, in the contemporary treatment era, similar first-year responses are observed in treatment-naive patients who start ART in clinical trials and in those who start ART in routine care.
